Dr. Fleischman’s laboratory studies how hematopoietic stem cells with myeloid malignancy associated mutations gain a selective advantage over wild-type hematopoietic stem cells and lead to hematologic malignancies. Her research program examines Myeloproliferative neoplasm (MPN), specifically the impact the competition between JAK2V617F mutant and wild-type hematopoietic stem cells. Her primary focus has been on the role of inflammation as a driver of MPN disease initiation by investigating whether persistent Toll Like Receptor (TLR) Signaling is responsible for the chronic inflammation seen in MPN patients. One of Dr. Fleischman’s graduate students, Betty (Hew Yeng) Lai, a 2020-2021 training grant awardee, graduated in August, 2021.